2017
DOI: 10.2174/1874285801711010316
|View full text |Cite
|
Sign up to set email alerts
|

Live Attenuated Reassortant Vaccines Based on A/Leningrad/134/17/57 Master Donor Virus Against H5 Avian Influenza

Abstract: Background:The H5N1 avian influenza was first recognized in humans in Hong Kong 20 years ago. Current enzootic spread of highly pathogenic H5N1 virus among wild and domestic poultry and a number of severe human respiratory diseases caused by this pathogen have stimulated necessity of development of potentially pandemic influenza vaccines.Discussion:In the past few years, significant research was conducted on how to prevent H5N1 influenza. Live, attenuated cold–adapted reassortant influenza vaccine (LAIV) is co… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2018
2018
2021
2021

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 46 publications
0
3
0
Order By: Relevance
“…A tailored mosaic peptide vaccine might be the best way to circumvent influenza virus escape, but on a population level for vaccine rollout would be impractical considering HLA selection for full-length proteins and immune competition during T cell priming, this area of research needs further exploration. The H5-derived NP protein is already able to be interchanged in the Leningrad LAIV backbone, demonstrating the possibility of a mosaic approach to incorporating T cell peptide variants with current methods [ 190 ].…”
Section: Universal Vaccine May Still Need To Thwart Viral Escapementioning
confidence: 99%
“…A tailored mosaic peptide vaccine might be the best way to circumvent influenza virus escape, but on a population level for vaccine rollout would be impractical considering HLA selection for full-length proteins and immune competition during T cell priming, this area of research needs further exploration. The H5-derived NP protein is already able to be interchanged in the Leningrad LAIV backbone, demonstrating the possibility of a mosaic approach to incorporating T cell peptide variants with current methods [ 190 ].…”
Section: Universal Vaccine May Still Need To Thwart Viral Escapementioning
confidence: 99%
“…There are two different types of live attenuated influenza vaccines (LAIV) commercially available, a quadrivalent vaccine, commercially known as FluMist ( Table 1 and Figure 2 ), which came in the market in 2003 in USA, and a trivalent vaccine created by the Institute of Experimental Medicine, St Petersburg, Russia. The Russian vaccine has been in the market for more than 50 years [ 173 , 174 ] and is based on cold–adapted A/Leningrad/134/17/57 (H2N2) (Len–MDV) and B/USSR/60/69 Master Donor Viruses (MDVs) with the addition of a circulating seasonal strain [ 175 ]. The quadrivalent vaccine is based on the “Ann Arbour” backbone (A/Ann Arbor/6/60 and B/Ann Arbor/1/66) and contains two B strains (B/Yamagata/16/88 and the B/Victoria/2/87 lineages), in addition to a A/H1N1 and a A/H3N2 strain [ 176 ].…”
Section: Nsv Vaccines On the Market Or Under Developmentmentioning
confidence: 99%
“…There are several H5 vaccine candidates based on a master donor of influenza A virus (IAV), for example, H5N1, H5N2, H5N8, and other strains [14][15][16]. Some of these vaccines have been evaluated in clinical trials [17,18].…”
Section: Introductionmentioning
confidence: 99%